Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New MAP3K5 inhibitors discovered at CJ HealthCare

May 11, 2020

Positive topline data presented from phase IIa study of HTD-1801 in NASH and T2DM

May 8, 2020

New SERPINA1 modulators presented by Vertex Pharmaceuticals

May 7, 2020

Genzyme initiates phase III study of venglustat in late-onset GM2 gangliosidosis

May 6, 2020

Where exercise-induced IL-6 comes and goes

May 6, 2020

New SSTR5 agonists presented by Heptares Therapeutics

May 5, 2020

Intarcia Therapeutics discloses new amylin analogues

May 5, 2020

Insulin cuts both ways in vasculature

May 5, 2020

European Commission approves Ruconest to treat HAE attacks in children

April 30, 2020

First patient dosed in proof-of-concept of OTL-201 gene therapy

April 29, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...